{"contentid": 488558, "importid": NaN, "name": "First-quarter sales and earnings down at Recordati", "introduction": "Shares of Italian drugmaker Recordati fell 2.5% to 44.70 euros, after the company posted financial results for the first quarter of 2021 today.", "content": "<p>Shares of Italian drugmaker Recordati (RECI: MI) fell 2.5% to 44.70 euros, after the company posted financial results for the first quarter of 2021 today.&nbsp;</p>\n<p>Consolidated net revenue was 384.8 million euros ($464.8 million) in the first quarter (-10.3% or -6.8% at constant exchange rate).</p>\n<p>Earnings before interest, taxes, depreciation and amortization (EBITDA) came in at 150.0 million euros, -13,2%. Operating income was 124.9 million euros, -15.9%. Net income was 89.9 million euros, -19.2%. Adjusted net income was 104.4 million, -16.6%.</p>\n<p>Despite the drop in sales, financial results for the first quarter were in line with expectations. Consistently with the objectives set at the beginning of 2021, Recordati says it expects a gradual recovery of the reference markets after the pandemic in the second half of the year, with lower incidence of seasonal flu infections throughout 2021.</p>\n<h2><strong>Product performances</strong></h2>\n<p>There was continued positive progress of Endo, delivering just over 26.1 million euros of revenue versus 14.7 million euros in same period last year.</p>\n<p>Eligard (leuprorelin acetate) integration is also on track, with 16.8 million of revenue, with very smooth transition with Astellas (TYO: 4503).</p>\n<p>Zanidip (lercanidipine) sales were 42.0 million euros, up 3.2% on the like 2020 period.</p>\n<p>Seloken/Seloken ZOK/Logimax (metoprolol/metoprolol+felodipine) sales were 24.8 million euros, down 18.2%.</p>\n<p>Livazo (pitavastatin) sales 11.4 million euros, down31.4%.</p>\n<p>Urorec (silodosin) sales were 16.0 million euros, down 40.9%.</p>\n<h2><strong>Three-year plan</strong></h2>\n<p>Recordati&rsquo;s board of directors also approved the plan for the 2021-2023 three-year period. The plan foresees that the development of the Recordati Group will continue to be supported by organic growth of the product portfolio, combined with acquisitions and business development operations aimed at strengthening the Group&rsquo;s presence in both the segments where it operates.</p>\n<p>For 2023, including the contribution of additional acquisitions that could be finalized over the plan period, this forecasts: revenue between 1,900 and 2,000 million euros, ahead of consensus forecasts of 1,809 euros; EBITDA between 720 and 760 million euros (704 million euros consensus); and adjusted net income between 530 and 560 million euros (510 million euros consensus).</p>", "date": "2021-05-06 15:16:00", "meta_title": "First-quarter sales and earnings down at Recordati", "meta_keywords": "Recordarti, Financial results, First-quarter, 2021", "meta_description": "First-quarter sales and earnings down at Recordati", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-06 15:12:46", "updated": "2021-05-06 15:23:39", "access": NaN, "url": "https://www.thepharmaletter.com/article/first-quarter-sales-and-earnings-down-at-recordati", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "recordati-large.jpg", "image2id": "recordati-small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": NaN, "topic_tag": "Financial, Management", "geography_tag": "Italy", "company_tag": "Recordati", "drug_tag": "Eligard, Livazo, Zanidip", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-06 15:16:00"}